Pharmaceutical Drug Manufacturers

20 April 2010- Diabetes mellitus is a lifestyle related chronic metabolic disorder caused due to the failure of body in producing hormone insulin and/or its inability to respond adequately to produced insulin. There are two categories of diabetes- Type 1 diabetes and Type 2 diabetes- with a share of 5-10% and 90-95% respectively of global diagnosed diabetes cases. The treatment of Type 1 diabetes depends basically on diabetic medical supplies, especially diabetes drugs and insulin. Type 2 diabetes is usually treated with intervention in diabetic patient's lifestyle. The World Health Organization (WHO) has estimated the number of diabetics to go beyond 350 million by year 2030. With this large number of global diabetic population, it surely is bound to have impact on diabetes market, especially diabetes drugs market. The Diabetes drugs market includes Injectables Market like that for Insulin and exenatide; and Oral Drugs Market like those for Metformin, Sulfonylureas, thaizolidinediones, dipeptidyl inhibitors, meglitinides, alpha glucosidase inhibitors, combination medications.

Read more about Anti-Diabetic Drugs

Diabetes Market 2007-2008

In 2007, the global diabetes market was worth over $25 billion and in 2008, it was worth $27.3 billion. In 2008, the diabetes market was led by insulin analogs that captured 45% of the market followed by glitazones with a share of 22.8%. The largest diabetes market in 2008 was the US with sales of $12.9 billion and a market share of 47.6%. However, the highest growth in sales y-o-y was recorded by many early emerging economies like UAE at 59.7%. In 2008, the prevalence of diabetes in all the leading diabetes market viz. US, Japan, UK, Germany, France, Spain, Italy, Brazil, China and India was 8.5% with Germany having the highest diabetes prevalence rate at 11.8%. However, diabetes is growing at an epidemic proportions that has also led to extensive R&D in its therapy area.

Diabetes Market 2010- Present Trends

Diabetes is prevailing worldwide and rising fast across the globe. Some of the causes for diabetes prevalence include increased life expectancy, inactive lifestyles, and rising incidence of obesity. Most of the developed and developing economies of the world experience all the three factors and thus diabetes prevalence over there is on epidemic measure. The diabetes drugs market of Brazil is continuously showing double digit growth rate. The insulin market of Russia is set to witness significant growth due to its estimated 20 million diabetes patients by 2025. China has already been recognized as diabetic capital of world with the highest number of diabetics. China alone is forecast to have more than 71 million diabetic patients by 2025. India, however is forecast to soon acquire the position of the diabetic capital of world,leaving behind China! Many pharmaceutical companies have already introduced easy-to-use insulin versions to acquire the major diabetes market share in the Indian diabetes drugs market.

Diabetes Market 2025- Future Predictions

Diabetes market has come up as one of the most significant sectors of the pharmaceutical industry. During the period 2010-2025, all the segments of diabetes market will grow at still faster rates. Here are some pointers that indicate towards the shape of the future Diabetes Market in 2025.

• The diabetes market will see launch of diabetic products with much superior performance.
• The R&D in the field of developing diabetes therapies will focus on technologies that increase clinical effectiveness, tolerability and ease of use.
• Among the available diabetes treatments, Insulin has already captured the largest diabetes market share of 45% and is forecast to dominate the market during 2010-2025.
• Talking of insulin, although insulin analogs have become well established in the diabetes market, the impact of inhaled insulin is yet to be seen in the future.
• Pre-insulin market is also a significant segment of the total diabetes market and it has developed many newer and safer diabetes therapies such as the DPP-IV inhibitors and GLP-1 analogs . The comparative performance of these diabetes therapies are predicted to shape the diabetes market 2013-2014 and in the long term till 2025.
• With the revised guidelines of FDA in December 2008, the pharmaceutical companies developing diabetes drugs are required to conduct deeper studies to avoid any 'unacceptable' cardiovascular risk. They now have to conduct meta analyses for cardiovascular safety in the Phase II and III trials of diabetes drugs and rule out the possibility of an increased cardiovascular disease risk by 80% or more. This, apart from making the regulatory environment challenging for the diabetes market will also lead to introduction of more safer anti diabetic drugs in the near future.

Also read Pharmaceutical Biotechnology Industry Report 2009-2010